Pharmaceutical company Venus Remedies today said that seven units at its Baddi plant in Himachal Pradesh have received the Good Manufacturing Practices (GMP) accreditation from Sudan's National Medicine and Poison Board.
The accreditation pertains to units that produce medicines for cancer, antibiotics, cardiovascular and other specialty injections, the company said in a statement.
"Venus is now looking forward to serve Sudan, which is the largest country in Africa. MENA (Middle East and North Africa) region is believed to be one of the most stringent regulatory approval systems across the globe," Venus Remedies Joint Managing Director Manu Chaudhary said.
Quoting CMS Sudan, the company said that the existing Sudanese Pharmaceutical market amounts to about USD 520 million, growing at 11 per cent annually.
The market is largely dependent upon imports, it added. Venus Remedies is also in the process of seeking registration for products from all the seven units. The company has already filed 17 critical care product dossiers mainly in the anti-cancer and antibiotics areas, it added.
Sudan is the tenth country in the African continent where Venus would have a strong presence. It has already made its presence felt in countries like Ethiopia, Kenya, Uganda, Botswana, Zimbabwe, Togo and South Africa.
More From This Section
"With this GMP, Venus today possesses 13 international GMP certifications from different countries of the world, including EU-GMP, which is valid for entire Europe for its super-specialty injectable manufacturing facilities," the statement said.
Stating that it has appointed one of the biggest pharmaceutical distributors in Sudan for promoting products, the company said it also plans to register its research products 'Sulbactomax' and 'Potentox' in the market.